Synthesis and evaluation of catechol derivatives as an amyloid-beta aggregation inhibitor

Department of Biochemical Engineering, Graduate School of Science and Engineering, Yamagata University, Yonezawa, Yamagata 992-8510, Japan

OFusheng Xu, Miyu Okada, Misato Tajiri, Koki Makabe, Hiroyuki Konno

Keywords: Alzheimer's disease, Amyloid beta, catechol derivatives, Aggregation inhibition

Amyloid β (A β) is peptide consisting of 36-43 amino acid residues generated from amyloid β precursor protein (APP) [1]. A β fibrils exhibit self-propagating and its aggregations may lead to variations in clinical and pathological characteristics of Alzheimer's disease (AD). Therefore, inhibition of A β aggregation is considered to be an important means to effectively treat and inhibit Alzheimer's disease [2].

Clovamide (1) is a natural polyphenol product isolated from red clover. As a catechol derivative, clovamide (1) has anti-inflammatory and anti-oxidant effects. Dr. Tsunoda from the University of Tsukuba has demonstrated that the natural product clovamide has some activity to inhibit $A\beta$ aggregation [3]. However, we think that the presence of the L-dopa structure is the key to the activity of clovamide (1). After the synthesis of clovamide (1), we appropriately changed the structure of clovamide (1) to synthesize a series of catechol derivatives. We tested all the synthesized compounds for inhibition of $A\beta$ aggregation and found that five compounds showed potent inhibitory activity. These small molecules not only have excellent water solubility, but also have low or near-absence of cytotoxicity. We also proved our idea by transmission electron microscopy, particle radius, and other experiments, which are described in this paper.

$$\begin{array}{c} \text{HO} \\ \text{HO} \\ \text{HO} \\ \text{OH} \\ \text{OH} \\ \text{OH} \\ \text{OH} \\ \text{OH} \\ \text{HO} \\ \text{HO} \\ \text{OMe} \\ \text{HN} \\ \text{O} \\ \text{Clovamide (1)} \\ \\ \text{Catechol derivatives} \\ \end{array}$$

- 1) M. Walsh, D. J. Selkoe, J. Neurochem. 101 (2007) 1172-1184.
- 2) M. Tajiri, R. Yamada, M. Hotsumi, K. Makabe, H. Konno, Eur J Med Chem. 215 (2021) 113289.
- 3) T. Tsunoda, M. Takase, H. Shigemori, Bioorg. Med. Chem. 26 (2018) 32-2-3209.